Thermo Fisher Scientific (NYSE:TMO) Announces Quarterly Earnings Results, Beats Expectations By $0.32 EPS

Thermo Fisher Scientific (NYSE:TMO) announced its quarterly earnings results on Thursday. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32, FiscalAI reports. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the business earned $4.28 earnings per share. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific updated its FY 2026 guidance to 24.930-25.330 EPS.

Here are the key takeaways from Thermo Fisher Scientific’s conference call:

• Thermo Fisher reported a strong second quarter, with revenue up 10% to $11.99 billion, adjusted EPS up 13% to $6.03, and organic revenue growth of 5% ahead of prior guidance.
• Management said customer activity strengthened across end markets, with particular momentum in pharma/biotech, plus positive growth in academic and government, industrial and applied, and diagnostics and healthcare.
• The company raised full-year 2026 guidance for both revenue and EPS, now expecting $47.4 billion-$48.1 billion of revenue and adjusted EPS of $24.93-$25.33, reflecting stronger second-half expectations.
• Several growth initiatives performed well, including Clario and filtration/separation acquisitions, which management said are integrating smoothly and contributing to higher acquisition revenue and EPS expectations for the year.
• Thermo Fisher announced it will divest its microbiology business in the third quarter, and used $1 billion of expected proceeds for share repurchases in Q2; management said the divestiture will modestly reduce 2026 revenue and EPS.

Thermo Fisher Scientific Stock Up 8.7%

NYSE TMO traded up $45.92 during trading on Thursday, reaching $572.38. 1,505,888 shares of the company’s stock traded hands, compared to its average volume of 2,305,288. The firm has a market cap of $212.71 billion, a price-to-earnings ratio of 31.70, a price-to-earnings-growth ratio of 2.32 and a beta of 0.87. The company’s 50 day simple moving average is $488.92 and its two-hundred day simple moving average is $513.21. Thermo Fisher Scientific has a 12-month low of $435.27 and a 12-month high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Insiders Place Their Bets

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Institutional Trading of Thermo Fisher Scientific

Institutional investors have recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. raised its holdings in Thermo Fisher Scientific by 5.3% during the fourth quarter. Sunbelt Securities Inc. now owns 573 shares of the medical research company’s stock worth $332,000 after purchasing an additional 29 shares during the last quarter. Evansbrook LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $215,000. Birchwood Financial Partners Inc. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Strive Financial Group LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $2,209,000. Finally, Blue Sparrow LLC DE purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $16,167,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on TMO shares. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 price target on the stock. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Finally, Evercore set a $570.00 price target on Thermo Fisher Scientific in a report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $602.14.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher beat Q2 expectations, posting $6.03 adjusted EPS versus the $5.71 consensus and $11.99 billion in revenue versus $11.71 billion expected, helped by stronger customer activity across end markets and continued organic growth. Article Title
• Positive Sentiment: The company also raised FY2026 guidance, now calling for EPS of $24.93 to $25.33 and revenue of $47.4 billion to $48.1 billion, both above Wall Street estimates, which suggests management is seeing a healthier operating backdrop.
• Positive Sentiment: Earlier reports noted shares rose in premarket trading after the earnings beat, reflecting investor optimism that demand is improving across Thermo Fisher’s life sciences, diagnostics, and lab equipment businesses. Article Title
• Neutral Sentiment: ImmuPharma selected Thermo Fisher’s Patheon unit to manufacture its Kapiglucagon diabetes candidate, a modest business-development win that adds some incremental contract manufacturing exposure but is unlikely to move the stock on its own. Article Title

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.